Author: MyHairline Editorial Team Editorial review: MyHairline medical content review. Named clinician reviewer pending verified reviewer relationship and crawlable bio. Last updated: May 2026
Educational use only. This article is not medical advice, is not a prescription, and does not endorse any specific telehealth platform. Finasteride is a prescription medication and requires a licensed clinician's evaluation. The Myhairline.ai analyzer is an educational classification tool and does not prescribe.
Last October, a 28-year-old software developer named Marcus in Denver told me he'd been toggling between the Hims checkout page and a PubMed search for finasteride side effects for three straight weeks. "I'd add it to my cart, read another Reddit horror story, close the tab, then come back two days later," he said. His vertex was thinning at roughly a Norwood 3 vertex. He wasn't sure whether the telehealth route was a shortcut or a compromise. He isn't unusual. "Finasteride hims" is one of the most-typed hair loss queries in the country, and the people searching it want wildly different things: some want pricing, some want safety data, some just want someone to tell them whether it works.
This article is about the clinical evidence. It doesn't prescribe, doesn't rank telehealth providers, and doesn't tell you what to do. But it does try to give you enough information to stop toggling between checkout and PubMed at 1 a.m.
The Enzyme, the Hormone, the Hair
Finasteride is a competitive inhibitor of the type II isoform of 5-alpha-reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). At a 1 mg daily oral dose, finasteride reduces serum DHT by roughly 65 to 70 percent and scalp DHT by approximately 60 to 65 percent, according to pharmacokinetic data published in the Journal of Clinical Endocrinology and Metabolism in 1999.
DHT is the molecule that slowly strangles susceptible hair follicles. Think of it like turning the thermostat down on a radiator: the follicle doesn't die immediately, it just produces thinner, shorter, lighter hairs over years until it effectively stops producing visible ones at all. Finasteride turns the thermostat back up. Not all the way, and not forever, but enough to matter for most men.
The pivotal evidence comes from the 1998 Kaufman trials published in the Journal of the American Academy of Dermatology. Two pooled 12-month, placebo-controlled trials enrolled 1,553 men aged 18 to 41 with vertex-pattern androgenetic alopecia. At month 12, roughly 48 percent of men on 1 mg finasteride showed visible improvement on global photographic assessment. Another 42 percent stabilized (no further loss). About 7 percent continued to lose hair despite treatment.
The two-year extension, published in the same journal in 1999, confirmed the benefit held. By five years (2002 follow-up), 90 percent of treated men had maintained or improved their hair status, compared with 75 percent of placebo-treated men who continued losing ground. Those numbers are genuinely impressive for a single daily pill.
Here's the catch: the frontal hairline data are weaker. A separate 1-year study published in 2002 in the Journal of the American Academy of Dermatology examined frontal scalp response specifically and found smaller, though still statistically significant, improvements. If your primary concern is a receding hairline rather than vertex thinning, finasteride helps, but expectations should be calibrated accordingly.
The Side-Effect Conversation Nobody Handles Well
Sexual side effects are the elephant in every finasteride discussion, and both sides of the debate tend to handle it badly. The "it's totally safe, just take it" camp ignores legitimate concerns. The "it ruined my life" camp extrapolates from a signal that, while real, is difficult to quantify.
The trial data: across the original 12-month Kaufman studies, sexual side effects (decreased libido, erectile dysfunction, ejaculation disorders) occurred in approximately 3.8 percent of treated men versus 2.1 percent on placebo. That's an absolute difference of about 1.7 percentage points. The majority of affected men saw resolution either with continued use or after stopping.
Post-marketing surveillance introduced the concept of post-finasteride syndrome (PFS), a pattern of persistent sexual, cognitive, and mood symptoms in some men who discontinued the drug. A 2020 systematic review in the Journal of the American Academy of Dermatology concluded that high-quality evidence for a causal link is limited but cannot be ruled out. The FDA has updated the prescribing label to acknowledge these post-marketing reports.
The honest framing: the trial-level risk is low. The post-marketing signal is real and its true magnitude remains uncertain. If you have a history of mood disorders, are concerned about sexual side effects, or plan to father children in the near term, these are things to discuss with a prescribing clinician before starting, not after.
Other important notes: finasteride is contraindicated in pregnancy (risk of feminization of a male fetus) and is generally avoided in women of childbearing potential. It also affects PSA values used in prostate cancer screening. If you're on finasteride and get a PSA test, tell the clinician interpreting the result.
Minoxidil: The Other Half of the Standard Protocol
Minoxidil, originally developed as an oral antihypertensive, works through a different mechanism entirely. The topical 2 percent and 5 percent formulations have been FDA-approved for androgenetic alopecia since the 1980s and 1990s. The exact mechanism isn't fully understood, but it appears to involve potassium-channel opening, prolonged anagen (growth) phase, and stimulated follicle proliferation.
The 2002 Olsen trials in the Journal of the American Academy of Dermatology compared 5 percent topical solution to 2 percent solution and placebo over 48 weeks and reported the 5 percent formulation produced 45 percent more hair growth than 2 percent at the primary endpoint. That's a meaningful difference, and it's why 5 percent is the standard recommendation.
Side effects are mostly local: scalp irritation, contact dermatitis, and a shedding phase in the first six to eight weeks that alarms people but is actually a sign the drug is working (old telogen hairs getting pushed out by new anagen hairs).
Oral low-dose minoxidil (typically 1.25 to 5 mg daily) is increasingly used off-label for patients who can't tolerate the topical formulation. Published case series in JAMA Dermatology and Australasian Journal of Dermatology report comparable efficacy with a different side-effect profile: hypertrichosis (hair growth in unwanted areas), fluid retention, and rare cardiovascular effects. It's not for everyone, and it requires closer monitoring.
Dutasteride: The Stronger Cousin
Dutasteride blocks both type I and type II isoforms of 5-alpha-reductase, reducing serum DHT by approximately 90 percent compared with finasteride's 65 to 70 percent. It's FDA-approved for benign prostatic hyperplasia in the U.S., approved for androgenetic alopecia in South Korea and several other countries, and used off-label here.
A 2017 randomized trial in the Journal of the American Academy of Dermatology compared dutasteride 0.5 mg daily to finasteride 1 mg daily over 24 weeks and reported greater hair-count improvements with dutasteride at the vertex. Side-effect profiles are broadly similar, though some series report slightly higher sexual side-effect rates with dutasteride. Its much longer half-life (about five weeks, versus six to eight hours for finasteride) also means that if you do experience side effects, they take longer to clear your system. That matters.
PRP, Microneedling, and Laser Devices
Platelet-rich plasma (PRP) involves drawing your blood, spinning it in a centrifuge to concentrate platelets, and injecting the result into your scalp. A 2019 meta-analysis in Dermatologic Surgery across 19 randomized trials found statistically significant improvements in hair density versus controls, but noted substantial protocol variation and limited long-term data. PRP is not FDA-cleared for hair restoration. Pricing in the U.S. typically runs $500 to $1,500 per session, with most published protocols calling for three to four sessions over six months and maintenance every six to twelve months.
Microneedling, alone or combined with topical minoxidil or PRP, has some supporting evidence. A 2013 trial in the International Journal of Trichology found that adding microneedling to 5 percent minoxidil produced significantly greater hair-count improvements than minoxidil alone over 12 weeks. Promising, though the study was small.
Low-level laser therapy (LLLT) has FDA clearance for several home-use devices. The published evidence is mixed. A 2020 review in Lasers in Medical Science reported small-to-moderate effect sizes in pooled randomized data, though many studies are short, industry-funded, or both. My genuinely opinionated take: LLLT devices are unlikely to hurt you, but they're the weakest evidence-backed option in this category and the marketing wildly outpaces the science.
What Telehealth Actually Gets You (and What It Doesn't)
Telehealth platforms like Hims, Keeps, Roman, and others have legitimately expanded access to finasteride and minoxidil prescribing. That's a real benefit. None of these platforms invented or own the underlying medications, all of which are generic. The pricing you see on these platforms reflects the asynchronous consultation, recurring shipment, and platform overhead, not the drug itself. Generic finasteride 1 mg, prescribed through any licensed clinician, is available at U.S. pharmacies for under $15 per month using standard discount programs. Generic minoxidil 5 percent solution is similarly cheap.
The clinical evaluation on most telehealth platforms is asynchronous, photo-based, and limited compared with sitting across from a dermatologist. For uncomplicated cases (otherwise healthy adult men with clearly androgenetic patterns), that's generally adequate. Where this falls apart is for anyone with confounding symptoms, suspected non-androgenetic alopecia (frontal fibrosing alopecia, lichen planopilaris, alopecia areata, telogen effluvium with unclear trigger, scarring patterns), or other medical concerns. Those people need in-person dermatologic evaluation before initiating medication. The Myhairline.ai analyzer is an educational triage tool, not a substitute for either pathway.
Marcus, the Denver developer, eventually had a ten-minute telehealth consultation and started finasteride. Six months later, he told me his vertex looks "maybe 20 percent better" in photos, though he's still not sure how much of that is the Rogaine he added at month two. The boring truth about hair loss treatment is that it's slow, the improvements are gradual, and the best results come from starting before you wish you had.
Common Questions About Finasteride and Telehealth Hair Loss Care
How long until I see results from finasteride? The published trials measured response at six and twelve months. Some men notice early changes by month three. Realistic expectation: meaningful change requires at least six months of continuous use, and full effect typically takes twelve to eighteen months.
What happens if I stop finasteride? Hair count and density generally return to the pre-treatment trajectory over roughly twelve months after discontinuation. Finasteride doesn't produce a durable change in the underlying androgenetic process. Stop taking it and you lose the gains.
Can I take finasteride and minoxidil together? Yes. They work through different mechanisms, are commonly prescribed together, and have published combination-trial evidence supporting additive benefit. Their side-effect profiles don't meaningfully overlap.
Is topical finasteride a real option? Topical finasteride formulations are increasingly available through telehealth and compounding pharmacies. A 2022 trial in the Journal of the European Academy of Dermatology and Venereology reported similar efficacy to oral finasteride with lower systemic DHT suppression. Long-term safety data are still accumulating.
What should I tell my dermatologist before starting? Disclose all current medications, any history of mood disorders, plans for fathering children in the near term, family history of prostate disease, and any concerns about sexual side effects. Routine baseline PSA testing in men over 40 is sometimes recommended because finasteride affects PSA interpretation.
Is the generic version the same as what Hims ships? Yes. Finasteride is finasteride. The generic molecule is identical to the branded version. What you're paying for on a telehealth platform is convenience and the consultation, not a different drug.
Do I need blood work before starting? Most prescribing guidelines don't require blood work for otherwise healthy young men starting finasteride for hair loss. But if you're over 40, have a family history of prostate disease, or have hormonal concerns, bloodwork (including baseline PSA and possibly a hormone panel) is reasonable to discuss with your clinician.
Continue Reading Across the Non-Surgical Treatments Cluster
This page is the cluster hub for Non-Surgical Treatments on Myhairline.ai. The pillar overview lives at The Norwood Scale: Complete Guide. Supporting articles:
- Finasteride Hair Loss: Complete Guide, finasteride mechanism and outcomes in depth.
- Medication For Hair Loss: Complete Guide, the full medication landscape.
- Dutasteride Vs Finasteride Hair Loss, head-to-head efficacy and safety.
- Prp And Microneedling For Hair Loss: Complete Guide, combination protocols.
- Prp Hair Restoration Woodland Hills: Complete Guide, PRP availability and pricing in a major U.S. market.
- Prp Hair Restoration Pittsburgh: Complete Guide, PRP availability and pricing in Pittsburgh.
- Prp Injection Austin: Complete Guide, PRP availability in Austin.
- Hair Loss Treatment Chevy Chase: Complete Guide, local market treatment landscape.
- What are good alternatives for micro pigment scalp treatment?, SMP alternatives.
- The Norwood Scale: Complete Guide to Male Pattern Hair Loss Stages, the pillar.
Key References
Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4):578-589.
Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology. 1999;40(6):930-937.
Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002;47(3):377-385.
Gupta AK, Bamimore MA. Finasteride versus dutasteride for androgenetic alopecia: a systematic review. Journal of the American Academy of Dermatology. 2022;87(5):1149-1151.
Dhurat R, Sukesh M, Avhad G, et al. A randomized evaluator-blinded study of effect of microneedling in androgenetic alopecia. International Journal of Trichology. 2013;5(1):6-11.
Gupta AK, Carviel J. A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia. Dermatologic Surgery. 2016;42(12):1335-1339.
Hamilton JB. Patterned loss of hair in man: types and incidence. Annals of the New York Academy of Sciences. 1951;53(3):708-728.
Norwood OT. Male pattern baldness: classification and incidence. Southern Medical Journal. 1975;68(11):1359-1365.